The incretin system is the reason a meal does not crash your blood sugar. When food hits your small intestine, specialized gut cells release hormones that prime the pancreas to release insulin before glucose levels even peak. Those hormones are the incretins, and they have become the most important drug targets in metabolic medicine.<\/p>\n
Two incretins matter most: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Glucagon, which is technically not an incretin, works in the opposite direction by raising blood sugar. Modern weight loss drugs are essentially incretin engineering exercises, with some adding back glucagon agonism to boost energy expenditure.<\/p>\n
Tirzepatide hits GLP-1 and GIP. Semaglutide hits only GLP-1. Retatrutide, in late-stage trials, hits all three. Each combination produces different metabolic effects, and understanding the differences shapes how clinicians match patients to treatments.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The incretin effect is the observation that oral glucose triggers far more insulin release than intravenous glucose at the same blood concentration.<\/strong> The difference is the gut. When glucose passes through the intestine, it triggers incretin hormone release, which amplifies insulin secretion at the pancreas.<\/p>\n Quick Answer: GLP-1 and GIP are the two main incretins, released by L cells and K cells in the gut<\/p>\n In healthy people, the incretin effect accounts for roughly 50 to 70% of post-meal insulin release. In type 2 diabetes, the incretin effect is markedly reduced. Knauf et al. (1986, Journal of Clinical Investigation) showed this difference in a classic study comparing oral and IV glucose responses.<\/p>\n The therapeutic insight is that boosting incretin signaling restores some of that lost insulin response. Drugs that mimic GLP-1 or block the enzyme that breaks down GLP-1 (DPP-4 inhibitors like sitagliptin) both work on this principle.<\/p>\n Beyond glucose control, the incretin system has effects on appetite, gastric motility, and energy expenditure. This is why GLP-1 receptor agonists produce weight loss in addition to A1C improvement, while older diabetes drugs typically did not.<\/p>\n Both hormones boost insulin secretion in response to glucose.<\/strong> They diverge almost everywhere else.<\/p>\n GLP-1 is released by L cells in the distal small intestine and colon. It suppresses appetite, slows gastric emptying, and inhibits glucagon release. Its effects on weight come mostly through brain receptors and gastric motility.<\/p>\n GIP is released by K cells in the duodenum and proximal jejunum. It has minimal effect on appetite on its own, does not slow gastric emptying, and may increase adipose tissue glucose and fat uptake. Historically GIP was seen as the wrong target for obesity because it seemed to promote fat storage.<\/p>\n That view shifted with tirzepatide. When GIP is paired with GLP-1, the combination produces stronger weight loss than GLP-1 alone. The leading theory is that GIP receptor activation in the brain modulates nausea, allowing higher effective GLP-1 dosing, while also boosting energy expenditure. The historical concern about GIP and fat storage may have applied only to GIP alone.<\/p>\n Glucagon is the metabolic counterweight to insulin.<\/strong> The pancreas releases it when blood sugar drops, signaling the liver to release stored glucose. In a healthy person, glucagon and insulin run in opposition to keep blood sugar stable.<\/p>\n In diabetes, glucagon is often inappropriately high after meals, which worsens hyperglycemia. GLP-1 suppresses glucagon, which is one mechanism behind its blood sugar effects. So why add glucagon agonism to obesity drugs? At supraphysiologic doses, glucagon receptor activation increases energy expenditure and lipolysis.<\/p>\n The challenge is balancing fat-burning effects against unwanted blood sugar elevation. Retatrutide, a GLP-1\/GIP\/glucagon triple agonist from Eli Lilly, is engineered to get the metabolic boost without the glycemic penalty. Phase 2 data (Jastreboff et al. 2023, NEJM) showed 24.2% weight loss at 48 weeks. The combination uses the GLP-1 and GIP components to control glucose while glucagon adds thermogenic and lipolytic effects.<\/p>\n DPP-4 is the enzyme that breaks down native GLP-1 and GIP within minutes.<\/strong> DPP-4 inhibitors like sitagliptin (Januvia) and linagliptin (Tradjenta) block that enzyme, extending the half-life of your own incretins.<\/p>\n The downside is that DPP-4 inhibitors only raise endogenous incretins to mid-physiologic levels. They control blood sugar but produce essentially no weight loss. GLP-1 receptor agonists, by comparison, push receptor activation to supraphysiologic levels far above what diet alone can reach.<\/p>\n This is why a patient with type 2 diabetes might switch from a DPP-4 inhibitor to semaglutide and see both better A1C control and meaningful weight loss. The mechanism is similar; the magnitude is not. DPP-4 inhibitors remain useful for patients who cannot tolerate injectables or who have mild diabetes without significant obesity.<\/p>\n Native GLP-1 is a 30-amino-acid peptide with a half-life of about 2 minutes.<\/strong> Semaglutide is a modified version of GLP-1 with three engineering changes: an amino acid substitution at position 8 to block DPP-4 cleavage, a fatty acid chain that binds albumin to slow renal clearance, and a linker that maintains receptor binding.<\/p>\n The result is a half-life of about 165 hours, which makes once-weekly injection practical. Liraglutide, the older once-daily GLP-1 agonist, uses similar fatty acid acylation but with a shorter chain and faster clearance. Its half-life is about 13 hours.<\/p>\n These engineering choices matter for clinical effect. Long half-lives produce steady receptor activation, which is what drives sustained appetite suppression. Short-acting GLP-1 agonists like exenatide twice daily have stronger effects on gastric emptying but weaker effects on weight.<\/p>\n Tirzepatide is a single molecule that binds both the GLP-1 receptor and the GIP receptor.<\/strong> The trick is balanced affinity. The drug is somewhat biased toward the GIP receptor, which initially raised concerns that it might emphasize the wrong pathway.<\/p>\n In practice, the dual signaling produces effects neither hormone achieves alone. SURPASS-2 (Frias et al. 2021, NEJM) showed tirzepatide outperformed semaglutide for A1C reduction in diabetes. SURMOUNT-1 showed superior weight loss in obesity.<\/p>\n The synergy may come from coverage of more receptor populations across the brain, gut, and adipose tissue. Coskun et al. (2018, Molecular Metabolism) characterized the original compound and showed that mice lacking the GIP receptor still benefited from tirzepatide GLP-1 component, but the combined effect required both receptors.<\/p>\n Amylin is a peptide co-secreted with insulin by pancreatic beta cells.<\/strong> It slows gastric emptying, suppresses glucagon, and reduces appetite through brainstem receptors. The synthetic amylin analog pramlintide (Symlin) has been on the market for years but has not been a commercial success.<\/p>\n CGRP (calcitonin gene-related peptide) shares overlapping receptor biology with amylin. Cagrilintide, a long-acting amylin analog from Novo Nordisk, is being studied combined with semaglutide. The combination product, CagriSema, showed 22.7% weight loss in phase 2 trials (Friedrichsen et al. 2023).<\/p>\n The logic is similar to GIP combinations: layer multiple satiety signals through different receptor pathways to get stronger effects than maxing out any single pathway. The next decade of obesity medicine will probably feature several such combinations as different sponsors layer different satiety hormones together.<\/p>\n Key Takeaway: Glucagon raises blood sugar but also increases thermogenesis when used therapeutically<\/p>\n Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, produces dramatic changes in incretin secretion.<\/strong> Food reaches the distal intestine faster, which triggers larger and earlier GLP-1 release.<\/p>\n Falken et al. (2011, Journal of Clinical Endocrinology and Metabolism) measured post-meal GLP-1 levels up to ten times higher after gastric bypass than before surgery. This endogenous incretin surge is thought to drive much of the appetite reduction and diabetes remission that follows surgery, often before any meaningful weight loss occurs.<\/p>\n This shared mechanism is why GLP-1 drugs sometimes match bariatric outcomes for weight and metabolism. Surgery cranks up your own incretin system; semaglutide and tirzepatide bypass that system entirely by acting at the receptor. The two approaches arrive at similar receptor activation through completely different routes.<\/p>\n Retatrutide is a single peptide engineered to activate GLP-1, GIP, and glucagon receptors simultaneously.<\/strong> The phase 2 trial published by Jastreboff et al. in NEJM (2023) randomized 338 adults with obesity and showed 24.2% weight loss at 48 weeks on the highest 12 mg dose.<\/p>\n That weight loss number is higher than anything in the GLP-1 or GLP-1\/GIP literature at the same time point. The mechanism is thought to combine GLP-1 appetite suppression, GIP energy expenditure effects, and glucagon-driven lipolysis and thermogenesis.<\/p>\n The phase 3 TRIUMPH program is enrolling, with primary results expected in 2026. If the phase 2 numbers hold, retatrutide would set a new ceiling for pharmacologic weight loss outside of surgery. Other triple agonists are also in development from multiple sponsors.<\/p>\n Compounded semaglutide and tirzepatide are made by licensed compounding pharmacies under section 503A and 503B of the federal Food, Drug, and Cosmetic Act.<\/strong> The active ingredients are the same peptides used in branded products. The molecules act on the same incretin receptors.<\/p>\n TrimRx works with FDA-registered compounding pharmacies that source pharmaceutical-grade active pharmaceutical ingredients. A free assessment quiz starts the clinical review process, and a clinician determines whether semaglutide, tirzepatide, or another option fits the patient profile.<\/p>\n The regulatory environment for compounding has evolved as FDA-declared shortages of branded products have ended. Personalized compounding for specific patient needs continues under the 503A and 503B pathways.<\/p>\n Choice depends on baseline weight, diabetes status, tolerability history, and patient preference.<\/strong> Tirzepatide typically produces stronger weight loss and may be a better fit for patients with higher BMI or with insulin resistance. Semaglutide has a longer real-world track record and a slightly different side effect profile.<\/p>\n A personalized treatment plan factors in cost, prior medication history, and titration tolerance. Some patients start on semaglutide and switch to tirzepatide if response is slower than expected. Others do the reverse if tirzepatide causes more GI side effects than tolerated.<\/p>\n For patients with type 2 diabetes, either drug is reasonable. The SUSTAIN and SURPASS trial programs have established efficacy and safety in this population. Most clinicians factor in the patient’s existing diabetes medication regimen when choosing.<\/p>\n The pipeline is rich.<\/strong> Beyond retatrutide and CagriSema, dozens of dual and triple agonists are in earlier development. Oral GLP-1 small molecules like orforglipron may reach approval. Monthly injectables like MariTide are progressing through trials.<\/p>\n The biology of the incretin system is constrained, and the maximum effect achievable through receptor activation has limits. Most analysts expect that by 2030, weight loss outcomes from pharmacologic treatment will exceed 25 to 30% in key trials. The clinical question is which combinations of receptors and which dosing approaches produce the best balance of efficacy, tolerability, and durability.<\/p>\n Bottom line: Retatrutide phase 2 (Jastreboff et al. 2023 NEJM) showed 24.2% weight loss at 48 weeks with triple agonism<\/p>\n On its own, yes. GLP-1 has strong effects on appetite and gastric emptying that GIP lacks. But the two together, as in tirzepatide, produce more weight loss than either alone.<\/p>\n Beta cell sensitivity to GIP is markedly reduced in type 2 diabetes, and overall GLP-1 secretion may be blunted. Incretin-based drugs work because they bypass the upstream defect.<\/p>\n GLP-1 agonists push receptor activation to supraphysiologic levels. DPP-4 inhibitors raise your own GLP-1 to high-normal levels. The first produces weight loss; the second usually does not.<\/p>\n Probably not for everyone. Triple agonists may produce stronger weight loss but could come with different side effect profiles. Phase 3 data will clarify which patients benefit most.<\/p>\n Partly. Surgery dramatically increases endogenous GLP-1 release after meals, and that increase is thought to drive much of the appetite and metabolic benefit beyond physical restriction.<\/p>\n Yes, when sourced from licensed compounding pharmacies using pharmaceutical-grade API. The active ingredient is identical; formulation and concentration can vary.<\/p>\n Activin receptor pathways and myostatin inhibitors are being studied to address muscle preservation during incretin-driven weight loss. Bimagrumab is one such candidate in early trials.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" The incretin system is the reason a meal does not crash your blood sugar.<\/p>\n","protected":false},"author":11,"featured_media":90068,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"GLP-1 vs GIP vs Glucagon: Understanding the Incretin System","_yoast_wpseo_metadesc":"The incretin system is the reason a meal does not crash your blood sugar.","_yoast_wpseo_focuskw":"incretin system explained","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-90069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90069"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90069\/revisions"}],"predecessor-version":[{"id":91586,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90069\/revisions\/91586"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90068"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Is GLP-1 Different From GIP?<\/h2>\n
What Does Glucagon Do, and Why Is It Being Added Back?<\/h2>\n
How Do DPP-4 Inhibitors Fit Into This Picture?<\/h2>\n
What Is the Difference Between Native GLP-1 and Semaglutide?<\/h2>\n
How Does Tirzepatide Pull Off Dual Agonism?<\/h2>\n
What Are Amylin and CGRP, and Why Do They Matter Here?<\/h2>\n
What Happens to Incretin Signaling After Bariatric Surgery?<\/h2>\n
What Is Retatrutide, and Is Triple Agonism the Next STEP?<\/h2>\n
How Do Compounded GLP-1 Medications Fit In?<\/h2>\n
How Do TrimRx Clinicians Choose Between Semaglutide and Tirzepatide?<\/h2>\n
What Does the Future of Incretin Therapy Look Like?<\/h2>\n
FAQ<\/h2>\n
Is GLP-1 Better Than GIP for Weight Loss?<\/h3>\n
Why Does the Incretin System Not Work as Well in Type 2 Diabetes?<\/h3>\n
What Is the Difference Between a GLP-1 Agonist and a DPP-4 Inhibitor?<\/h3>\n
Will Triple Agonists Replace Dual Agonists?<\/h3>\n
Does the Incretin System Explain Why Bariatric Surgery Works?<\/h3>\n
Are Compounded Versions of These Drugs the Same Molecule?<\/h3>\n
What Is the Next Big Target After Triple Agonists?<\/h3>\n